Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vaxigrip

Sanofi reception

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

First cancer drug wholly owned by company to be approved in past decade

- PMLiVE

Modest meeting sees only two drugs recommended by CHMP

Lilly’s migraine med Emgality receives negative opinion for label extension

Sanofi reception

Sanofi says it will spin out active ingredient business by 2022

New chief exec Paul Hudson continues revamp

- PMLiVE

As new coronavirus outbreaks emerge, fears of a global pandemic escalate

Increased quarantine measures are reported across the globe

- PMLiVE

US backs Sanofi’s ‘fast-track’ coronavirus vaccine

Development will tap into earlier work on the SARS virus

- PMLiVE

Sanofi highlights MS drug data as it swings to a loss in Q4

Reported a €10m net loss in the quarter

Sanofi reception

Sanofi indicted in France over epilepsy drug birth defects

Faces allegations over a failure to warn women about risks associated with drug

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

- PMLiVE

Givlaari, Rybelsus lead crowded CHMP recommendations

EU regulator delivered 15 positive opinions and no rejections

- PMLiVE

It’s Brexit day – now comes the really hard stuff

Months of trade negotiations between UK and EU lie ahead

Sanofi reception

Sanofi’s rare disease drug olipudase alfa scores in late-stage study

Met crucial endpoints across two clinical studies

- PMLiVE

Sanofi completes acquisition of immuno-oncology specialist Synthorx

Synthorx is now fully owned by the French drugmaker

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links